Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria...
-
date post
18-Dec-2015 -
Category
Documents
-
view
215 -
download
1
Transcript of Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria...
![Page 1: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/1.jpg)
Analysis of Winning Advertisements
![Page 2: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/2.jpg)
Agenda
• Recap Past Studies
• Review Objectives
• Review Criteria
• Evaluate New Rx Performance for Winners
• Next Steps
![Page 3: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/3.jpg)
Perspective
• Does Journal Advertising Work?
• Does Advertising Have an Impact on Rxs?
• How Much Advertising is Necessary?
![Page 4: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/4.jpg)
Chronology and review of significant research
![Page 5: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/5.jpg)
ROI Analysis of Pharmaceutical PromotionLandmark study
historical data for 1995-99
391 drugs, 16,696 monthly observations
Determined marginal ROI
JAD, $5.00 +/- $0.88
PME, $3.56 +/- $1.92
DET, $1.72 +/- $0.19
DTC, $0.19 +/- $0.52
Dartmouth Marginal ROI Study, 2001RAPP
![Page 6: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/6.jpg)
• Analysis of ROI for Pharmaceutical Promotion– Extended data 1995-2000; 21,436 monthly observations– Examples of findings:
• $500M+/1998-2000: All tactics generate positive returns for average brand, but under spending on JAD and PME
– Additional spend on journals could have very positive returns for both small brands and large brands
Yale Marginal ROI Study, 2002ARPP
![Page 7: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/7.jpg)
![Page 8: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/8.jpg)
•Select targeted physician specialties•Oncology•Pulmonary Disease•Psychiatry•Neurology
![Page 9: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/9.jpg)
• Analyze Top 10 Products for Each Specialty• Spend levels• Reach & Frequency Levels
![Page 10: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/10.jpg)
Baseline Study10 month advertising campaign
Follow-up StudyEvaluate Results
![Page 11: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/11.jpg)
Total of 203 insertions$1,083,466 in advertising space
•Oncology - $73,280•Pulmonary Disease - $91,925•Neurology - $99,639•Psych - $105,398•Primary Care - $432,577
![Page 12: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/12.jpg)
Pulmonary Disease – 75%Psychiatry – 54%Oncology – 48%Neurology – 43%
Monthly ExposuresMonthly Exposures
![Page 13: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/13.jpg)
Pulmonary Disease – 75%Psychiatry – 54%Oncology – 48%Neurology – 43%
Monthly ExposuresMonthly Exposures
![Page 14: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/14.jpg)
Baseline Post-Campaign
Yes 24% 45%
No 74% 54%
Not Sure 2% 1%
The Awareness increased by 89%!
Are you aware of the availability of the Directory of Prescription Drug Patient Assistance Programs, from (PhRMA)?
![Page 15: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/15.jpg)
• Neurologists were exposed least (43%/mo)– Awareness increased 69%
• Pulmonary Disease were exposed most (75%/mo)– Awareness increased by 117%
![Page 16: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/16.jpg)
Two Product-Specific Studies
Designed to measure the relationship of detailing and print advertising
![Page 17: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/17.jpg)
• Select two products in major therapeutic areas– No previous PCP promotion
– Patent-protected
– One year test period
![Page 18: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/18.jpg)
• Four Cells of 16,000 PCP’s– Control Group
– Low level of promotion
– Average level of promotion
– High level of promotion
![Page 19: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/19.jpg)
• Pretest each advertisement
• Launch Campaigns
• Six Month PosTest
– Ad Recognition
– Product Recall
– Correct Message Association
– New Rx’s
• New Rx Analysis
• Twelve Month Results
![Page 20: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/20.jpg)
• “B” PreTest– 57% physicians unsure/negative
• too busy, too crowded, too much information
– Recommended to change ad size from 2 pages to 4 pages
– Not Done
• Subsequent change of detail message
![Page 21: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/21.jpg)
Metrics did not change: PCP NRx
Mar-Aug ‘03 Mar-Aug ‘04 % Change
Control 5,707 8,287 45.2%
Cell I 5,438 7,845 44.3%
Cell II 5.946 8,718 46.5%
Cell III 6,713 9,650 43.8%
![Page 22: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/22.jpg)
• “A” PreTest– Good pretest acceptance
– Accepted visual elements
– Accepted headline
• Recommended message simplification– adjusted
![Page 23: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/23.jpg)
11
16
23
44
0
5
10
15
20
25
30
35
40
45
Control Low Cell Average Cell High Cell
Product Recall – six months
![Page 24: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/24.jpg)
21
44 45
58
0
10
20
30
40
50
60
Control Low Cell Average Cell High Cell
Ad Recognition – six months
![Page 25: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/25.jpg)
0
5
10
15
20
25
30
35
40
45
Control Low Cell Average Cell High Cell
3229 26
44
Correct Message Association – six months
![Page 26: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/26.jpg)
0
20
40
60
Control Low Cell Average Cell High Cell
.
.40% 40% 41% 42%
43%38%
46%52%
Company Records
Physicians’ Perception
Perception of Detailing – six months
![Page 27: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/27.jpg)
First Choice Therapy
31 3032
38
0
5
10
15
20
25
30
35
40
Percent
Control Cell 1 Cell 2 Cell 3
Product “A” Six Month PosTest
![Page 28: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/28.jpg)
0.1
9.79
0.1
11.07
0
2
4
6
8
10
12
% change
1st 6 Months 2nd 6 Months
Control
High cell
Change in NRx
![Page 29: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/29.jpg)
9.79
11.07 11.16
9
9.5
10
10.5
11
11.5
% change
1st 6Months
2nd 6Months
Post TestPeriod
High cell
(8 months)
Change in NRx
![Page 30: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/30.jpg)
Doctor’s Choice Awards
![Page 31: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/31.jpg)
Journal Advertisement Attributes – Doctors’ Choice QuestionnaireJournal Advertisement Attributes – Doctors’ Choice Questionnaire
• Prompts seeking more information or re-examination of treatment• Prompts seeking more information or re-examination of treatment• Helps with clinical decisions• Helps with clinical decisions
• Adds to information provided by company representative• Adds to information provided by company representative
• Has immediate appeal to gain interestHas immediate appeal to gain interest• Has immediate appeal to gain interestHas immediate appeal to gain interest• Communicates clearly and quickly• Communicates clearly and quickly
• Reminds about value of product prescribed• Reminds about value of product prescribed
![Page 32: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/32.jpg)
Doctor's Choice Awards 2006
• Majority of winning advertisement achieved increased New Rx's
![Page 33: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/33.jpg)
Doctor's Choice Awards 2007
• Newest findings
![Page 34: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/34.jpg)
![Page 35: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/35.jpg)
Once again, the overwhelming majority of winners gained New Rx marketshare
New Rx's data contributed by Verispan
Reach & Frequency data contributed by MARS Medical
![Page 36: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/36.jpg)
Lipitor
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
CardiovascularsCardiovasculars
![Page 37: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/37.jpg)
Lipitor
73
84
80
76
66
68
70
72
74
76
78
80
82
84
GP FP IM CA
*This is read as 76% of the Card universe was exposed *This is read as 76% of the Card universe was exposed to the Lipitor ad each month of the campaignto the Lipitor ad each month of the campaign
![Page 38: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/38.jpg)
Zovirax
0.00%
0.02%
0.04%
0.06%
0.08%
0.10%
0.12%
Generic environmentGeneric environment
DermatologicalsDermatologicals
![Page 39: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/39.jpg)
Zovirax
54
0
10
20
30
40
50
60
Derm
![Page 40: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/40.jpg)
Novolog FlexPen
0.00%
0.50%
1.00%
1.50%
2.00%
2.50%
DiabetesDiabetes
![Page 41: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/41.jpg)
Novolog FlexPen
49
0
5
10
15
20
25
30
35
40
45
50
Diabetes/Endo
![Page 42: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/42.jpg)
Zyvox
0.00%
0.02%
0.04%
0.06%
0.08%
0.10%
0.12%
Amoxicillin in group
Anti-InfectivesAnti-Infectives
![Page 43: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/43.jpg)
Zyvox
82
0
10
20
30
40
50
60
70
80
90
ID
![Page 44: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/44.jpg)
Halflytely
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
GastroenterologicalsGastroenterologicals
![Page 45: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/45.jpg)
Halflytely
62
0
10
20
30
40
50
60
70
Gastro
![Page 46: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/46.jpg)
Keppra
0.00%
0.50%
1.00%
1.50%
2.00%
2.50%
NeurologicalsNeurologicals
![Page 47: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/47.jpg)
Keppra
62
0
10
20
30
40
50
60
70
Neuro
![Page 48: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/48.jpg)
NuvaRing
0.00%
1.00%
2.00%
3.00%
4.00%
5.00%
6.00%
7.00%
Obstetricals/GynecologicalsObstetricals/Gynecologicals
![Page 49: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/49.jpg)
NuvaRing
73
0
10
20
30
40
50
60
70
80
OB/GYN
![Page 50: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/50.jpg)
Tarceva
0.00%
0.20%
0.40%
0.60%
0.80%
1.00%
1.20%
OncologicalsOncologicals
![Page 51: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/51.jpg)
Tarceva
83
0
10
20
30
40
50
60
70
80
90
Oncologists
![Page 52: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/52.jpg)
Gardasil
0
0.05
0.1
0.15
0.2
0.25
PediatricsPediatrics
![Page 53: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/53.jpg)
Gardasil
5760
36
54
0
10
20
30
40
50
60
GP FP IM Ped
![Page 54: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/54.jpg)
Lunesta
12.00%
12.50%
13.00%
13.50%
14.00%
14.50%
15.00%
PsychiatricsPsychiatrics
![Page 55: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/55.jpg)
Lunesta
73
85
7468
47
0
10
20
30
40
50
60
70
80
90
GP FP IM PSY OB
![Page 56: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/56.jpg)
Flomax
36.00%
36.50%
37.00%
37.50%
38.00%
38.50%
39.00%
39.50%
40.00%
40.50%
41.00%
UrologicalUrological
![Page 57: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/57.jpg)
Flomax
88
0
10
20
30
40
50
60
70
80
90
Uro
![Page 58: Analysis of Winning Advertisements. Agenda Recap Past Studies Review Objectives Review Criteria Evaluate New Rx Performance for Winners Next Steps.](https://reader036.fdocuments.in/reader036/viewer/2022062515/56649d245503460f949fae11/html5/thumbnails/58.jpg)
Conclusions
• Identify effective messages/creative
• Measure New Rx’s Over Time
• Successful messages are effective with ample execution
The winning products continue to demonstrate success in recognition and performance